



October 2024

Dear Sickle Cell Disease Warriors,

By now you may be aware Pfizer has [announced](#) that at this time, it is voluntarily withdrawing OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) in all markets where it is approved. We want you to know that we did not make this decision lightly and your safety was our top consideration when making this decision. Patient safety has and will always be our top priority.

The whole team at Pfizer is incredibly saddened – both professionally and personally – by this decision. We’ve heard directly from many of you and the impact this is having on you and your loved ones is not lost on us. Please know that we appreciate all feedback and are taking it to heart as we develop a plan to inform and support the SCD community moving forward.

We’ve also heard that you felt blindsided by this decision. Please know that we shared this news with you as quickly as we could and with your safety foremost in our minds based on legal and regulatory guardrails under which the pharmaceutical industry operates. These regulations dictated how and when we could share the announcement; yet we understand that it may have caught you off guard, and for that we are truly sorry.

We will continue to update you as fully and as quickly as we can. In the meantime, you may consider the following:

- **Connect with a Patient Affairs Liaison:** The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. To contact a PAL, visit [www.togetherforrare.com](http://www.togetherforrare.com), click on “schedule a meeting with your PAL” in the center of the page and fill in the three prompts. Your local PAL will reach out to you shortly.
- **Visit [www.sicklecellspeaks.com](http://www.sicklecellspeaks.com)** for more information on sickle cell disease diagnosis, management, and support resources.
- **Return unused Oxbryta pills & be reimbursed:** To properly dispose of unused medication, please call a dedicated Oxbryta line during normal business hours, (Mon.-Fri. 8:00 am – 5:00 pm ET) at 888-548-8521. **At no cost to you**, we will take your information and send you a return kit within 3-5 business days. You will then fill in the enclosed form, seal the package, adhere the label and either drop off at a local UPS store or call UPS to pick it up. **You will be reimbursed for the amount you paid out-of-pocket for your Oxbryta.**

During a discussion we had with SCD Warriors following this announcement, we heard “don’t forget us.” We have not forgotten you, we will not forget you, and we remain committed to our research to



find much needed treatment options for people living with sickle cell disease. We will continue to update you as fully and as quickly as we can. Our thoughts continue to be with you.

With empathy, gratitude, and continued commitment,

The Pfizer SCD Team

Please see [Full Prescribing Information](#), including [Patient Information](#), for OXBRYTA. Patients with additional questions about OXBRYTA can also contact Pfizer Medical Information at 1-800-438-1985.